Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, and commercializing transformative medicines for people with serious diseases, with particular emphasis on specialty markets. The company's website is www.vrtx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vertex Pharmaceuticals does
In the company’s own words
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, and commercializing transformative medicines for people with serious diseases, with particular emphasis on specialty markets. The company's website is www.vrtx.com.
Vertex operates across multiple therapeutic areas with an established portfolio of approved medicines and an extensive clinical pipeline. In cystic fibrosis, the company markets five CFTR modulators including ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which are used by approximately three-quarters of CF patients in major markets. For hemoglobinopathies, Vertex offers CASGEVY, an ex-vivo CRISPR/Cas9-based gene-editing therapy approved for severe sickle cell disease and transfusion-dependent beta thalassemia. The company also markets JOURNAVX, a first-in-class oral pain signal inhibitor approved in 2025 for moderate-to-severe acute pain in adults.
The company's mid- and late-stage clinical pipeline includes five pivotal programs spanning multiple disease areas. Povetacicept, a dual BAFF and APRIL inhibitor, is in Phase 3 development for IgA nephropathy and primary membranous nephropathy, with regulatory submissions underway. Inaxaplin, a small molecule APOL1 inhibitor, is in Phase 2/3 development for APOL1-mediated kidney disease. Suzetrigine, a selective NaV1.8 pain signal inhibitor, is being evaluated in two Phase 3 trials for diabetic peripheral neuropathy. Zimislecel, an allogeneic stem cell-derived islet cell therapy, completed enrollment in Phase 1/2/3 trials for type 1 diabetes. Additionally, VX-670, an oligonucleotide therapeutic, is in Phase 1/2 development for myotonic dystrophy type 1.
Vertex's strategy emphasizes serial innovation, combining internal research with strategic acquisitions and collaborations. Notable acquisitions include Alpine Immune Sciences for povetacicept development and Semma Therapeutics for the T1D program. The company collaborates with CRISPR Therapeutics on gene-editing therapies, Moderna on mRNA therapeutics for cystic fibrosis, and Entrada Therapeutics on intracellular delivery technologies. Vertex maintains a strong intellectual property portfolio with multiple issued patents protecting its marketed products and pipeline candidates across major markets globally.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 875320
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vertex Pharmaceuticals — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Vertex Pharmaceuticals · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Vertex Pharmaceuticals’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vertex Pharmaceuticals and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vertex Pharmaceuticals's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vertex Pharmaceuticals's last four quarterly filings that the numbers alone won't show?”